[1] Mohaghegh MA, Yazdani H, Hadipour M, Namdar F, Azami M, Kalani H, et al. Seroprevalence of
Toxoplasma gondii infection among patients admitted to Al-zahra hospital, Isfahan, Iran. J Ayub Med Coll Abbottabad. 2015;27:767-70. PMID: 27004318.

[2] Ferguson DJ. Toxoplasma gondii: 1908-2008, homage to Nicolle, Manceaux and Splendore. Mem Inst
Oswaldo Cruz. 2009;104:133-48. PMID:19430635.

[3] Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and
sporozoites and biology and development of tissue cysts. Clin Microbiol Rev. 1998;11:267-99. PMID: 9564564.

[4] Halonen SK, Weiss LM. Toxoplasmosis. Handb Clin Neurol. 2013;114:125-45. PMID: 23829904.

[5] Rostami-Nejad M, Cheraghipour K, Nazemalhosseini Mojard E, Moradpour K, Razaghi M, Dabiri H.
Seroprevalence and risk factors for Toxoplasma infection in a large cohort of pregnant women in
Rural and Urban areas. HealthMED. 2011;5:338-43.

[6] Monney T, Debache K, Hemphill A. Vaccines against a major cause of abortion in cattle, Neospora
caninum infection. Animals (Basel). 2011;1:306-25. PMID: 26486502.

[7] Innes EA, Vermeulen AN. Vaccination as a control strategy against the coccidial parasites Eimeria,
Toxoplasma and Neospora. Parasitology. 2006;133:S145-68. PMID: 26486502.

[8] Liu Q, Singla LD, Zhou H. Vaccines against Toxoplasma gondii: status, challenges and future directions.
Hum Vaccin Immunother. 2012;8:1305-8. PMID: 22906945.

[9] Zhang NZ, Wang M, Xu Y, Petersen E, Zhu XQ. Recent advances in developing vaccines against
Toxoplasma gondii: an update. Expert Rev Vaccines. 2015;14:1609-21. PMID: 26467840.

[10] McLeod R, Frenkel JK, Estes RG, Mack DG, Eisenhauer PB, Gibori G. Subcutaneous and intestinal
vaccination with tachyzoites of Toxoplasma gondii and acquisition of immunity to peroral and congenital toxoplasma challenge. J Immunol. 1988;140:1632-7. PMID: 3346545.

[11] Buxton D, Innes EA. A commercial vaccine for ovine toxoplasmosis. Parasitology. 1995;110:S11-6. PMID:
7784124.

[12] Gigley JP, Fox BA, Bzik DJ. Long-term immunity to lethal acute or chronic type II Toxoplasma gondii
infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain. Infect Immun. 2009;77:5380-8. PMID:19797073.

[13] Lu F, Huang S, Kasper LH. The temperature-sensitive mutants of Toxoplasma gondii and ocular
toxoplasmosis. Vaccine. 2009;27:573-80. PMID:19026704.

[14] Innes EA, Bartley PM, Maley S, Katzer F, Buxton D. Veterinary vaccines against Toxoplasma gondii.
Mem Inst Oswaldo Cruz. 2009;104:246-51. PMID:19430650.

[15] Lipska A, Wysocka J, Turowski D. Immune response and diagnostic aspects during Toxoplasma gondii
infection. Wiad Parazytol. 2000;46:315-25. PMID:16883686.

[16] Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, Kuhn R, et al. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol. 1996;157:798-05. PMID:8752931.

[17] Walker DM, Oghumu S, Gupta G, McGwire BS, Drew ME, Satoskar AR. Mechanisms of cellular invasion
by intracellular parasites. Cell Mol Life Sci. 2014;71:1245-63. PMID:24221133.

[18] Suzuki Y, Wang X, Jortner BS, Payne L, Ni Y, Michie SA, et al. Removal of Toxoplasma gondii cysts from
the brain by perforin-mediated activity of CD8+ T cells. Am J Pathol. 2010;176:1607-13. PMID: 20167872.

[19] Miller CM, Boulter NR, Ikin RJ, Smith NC. The immunobiology of the innate response to Toxoplasma
gondii. Int J Parasitol. 2009;39:23-39. PMID:18775432.

[20] Montoya JG, Lowe KE, Clayberger C, Moody D, Do D, Remington JS, et al. Human CD4+ and CD8+ T
lymphocytes are both cytotoxic to Toxoplasma gondii-infected cells. Infect Immun. 1996;64:176-81.
PMID:8557337.

[21] Fachado A, Rodriguez A, Angel SO, Pinto DC, Vila I, Acosta A, et al. Protective effect of a naked DNA
vaccine cocktail against lethal toxoplasmosis in mice. Vaccine. 2003;21:1327-35. PMID:12615427.

[22] Sullivan WJ, Jr., Jeffers V. Mechanisms of Toxoplasma gondii persistence and latency. FEMS Microbiol
Rev. 2012;36:717-33. PMID:22091606.

[23] Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect.
2002;8:634-40. PMID:12390281.

[24] Jongert E, Roberts CW, Gargano N, Forster-Waldl E, Petersen E. Vaccines against Toxoplasma gondii:
challenges and opportunities. Mem Inst Oswaldo Cruz. 2009;104:252-66. PMID:19430651.

[25] Leyva R, Herion P, Saavedra R. Genetic immunization with plasmid DNA coding for the ROP2 protein
of Toxoplasma gondii. Parasitol Res. 2001;87:70-9. PMID:11199854.

[26] Ju CH, Chockalingam A, Leifer CA. Early response of mucosal epithelial cells during Toxoplasma gondii
infection. J Immunol. 2009;183:7420-7. PMID:19917706.

[27] Rostami Nejad M, Sherafat SJ, Roshani M, Telkabadi M, Lahmi F, Cheraghipour K, et al. The evaluation
of interleukin-8 chemokine in chronic and acute Toxoplasma gondii infection. Gastroenterol Hepatol
Bed Bench. 2011;4:34-7. PMID:24834153.

[28] Sabin AB, Olitsky PK. Toxoplasma and obligate intracellular parasitism. Science. 1937;85:336-8.
PMID:17815128.

[29] Lindsay DS, Blagburn BL, Dubey JP. Safety and results of challenge of weaned pigs given a
temperature-sensitive mutant of Toxoplasma gondii. J Parasitol. 1993;79:71-6. PMID:8437061.

[30] Cutchins EC, Warren J. Immunity patterns in the guinea pig following Toxoplasma infection and
vaccination with killed Toxoplasma. Am J Trop Med Hyg. 1956;5:197-09. PMID:13302615.

[31] Krahenbuhl JL, Ruskin J, Remington JS. The use of killed vaccines in immunization against an
intracellular parasite: Toxoplasma gondii. J Immunol. 1972;108:425-31. PMID:5049090.

[32] Wilkins MF, O’Connell E, Te Punga WA. Toxoplasmosis in sheep III. Further evaluation of the ability of
a live Toxoplasma gondii vaccine to prevent lamb losses and reduce congenital infection following
experimental oral challenge. N Z Vet J. 1988;36:86-9. PMID:16031449.

[33] Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes
in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii
vaccine. J Immunol. 1991;146:286-92. PMID:1670604.

[34] Escajadillo A, Frenkel JK. Experimental toxoplasmosis and vaccine tests in Aotus monkeys. Am J Trop
Med Hyg. 1991;44:382-9. PMID:2042705.

[35] Chartier C, Mallereau M. Vaccinal efficacy of Toxoplasma gondii S48 strain tested in an experimenal
trial in goats. Annales de Medecine Veterinaire. 2001;145(3):202-9.

[36] Bahia-Oliveira LM, Jones JL, Azevedo-Silva J, Alves CC, Orefice F, Addiss DG. Highly endemic,
waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg Infect Dis. 2003;9:55-62.
PMID:12533282.

[37] Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol.
2000;30:1217-58. PMID:11113252.

[38] Freyre A, Choromanski L, Fishback JL, Popiel I. Immunization of cats with tissue cysts, bradyzoites, and
tachyzoites of the T-263 strain of Toxoplasma gondii. J Parasitol. 1993;79:716-9. PMID:8410543.

[39] Ismael AB, Dimier-Poisson I, Lebrun M, Dubremetz JF, Bout D, Mevelec MN. Mic1-3 knockout of
Toxoplasma gondii is a successful vaccine against chronic and congenital toxoplasmosis in mice. J
Infect Dis. 2006;194:1176-83. PMID:16991094.

[40] Wales A, Kusel JR. Biochemistry of irradiated parasite vaccines: suggested models for their mode of
action. Parasitol Today. 1992;8:358-63. PMID:15463538.

[41] Seah SK, Hucal G. The use of irradiated vaccine in immunization against experimental murine
toxoplasmosis. Can J Microbiol. 1975;21:1379-85. PMID:1182614.

[42] Zorgi NE, Costa A, Galisteo AJ, Jr., do Nascimento N, de Andrade HF, Jr. Humoral responses and
immune protection in mice immunized with irradiated T. gondii tachyzoites and challenged with three genetically distinct strains of T. gondii. Immunol Lett. 2011;138:187-96. PMID:21545808.

[43] Hiramoto RM, Galisteo AJ, do Nascimento N, de Andrade HF, Jr. 200 Gy sterilised Toxoplasma gondii
tachyzoites maintain metabolic functions and mammalian cell invasion, eliciting cellular immunity and
cytokine response similar to natural infection in mice. Vaccine. 2002;20:2072-81. PMID:11972976.

[44] Falcon J, Freyre A. Toxoplasma gondii: prototype immunization of lambs against formation of muscle
and brain cysts. Vet Parasitol. 2009;166:15-20. PMID:19729248.

[45] Garcia JL, Gennari SM, Navarro IT, Machado RZ, Sinhorini IL, Freire RL, et al. Partial protection against
tissue cysts formation in pigs vaccinated with crude rhoptry proteins of Toxoplasma gondii. Vet
Parasitol. 2005;129:209-17. PMID:15845275.

[46] Freyre A, Falcon J, Mendez J, Gonzalez M. Toxoplasma gondii: an improved rat model of congenital
infection. Exp Parasitol. 2008;120:142-6. PMID:18634785.

[47] Zhao Y, Huang B, Huang S, Zheng H, Li YQ, Lun ZR, et al. Evaluation of the adjuvant effect of pidotimod
on the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models. Parasitol
Res. 2013;112:3151-60. PMID:23783399.

[48] Yin H, Zhao L, Wang T, Zhou H, He S, Cong H. A Toxoplasma gondii vaccine encoding multistage antigens
in conjunction with ubiquitin confers protective immunity to BALB/c mice against parasite infection.
Parasit Vectors. 2015;8:498. PMID: 26420606.

[49] Waldeland H, Frenkel JK. Live and killed vaccines against toxoplasmosis in mice. J Parasitol. 1983;69:60-
5. PMID:6827446.

[50] Khan IA, Casciotti L. IL-15 prolongs the duration of CD8+ T cell-mediated immunity in mice infected
with a vaccine strain of Toxoplasma gondii. J Immunol. 1999;163:4503-9. PMID:10510393.

[51] Wang Y, Yin H. Research progress on surface antigen-1 (SAG1) of Toxoplasma gondii. Parasit Vectors.
2014;7:180. PMID:24726014.

[52] Fox BA, Bzik DJ. Avirulent uracil auxotrophs based on disruption of orotidine-5’-monophosphate
decarboxylase elicit protective immunity to Toxoplasma gondii. Infect Immun. 2010;78:3744-52.
PMID:20605980.

[53] Weiss L, Kim K. Toxoplasma gondii: the model apicomplexan. Perspectives and methods. London:
Academic Press, 2013.

[54] Mercier C, Howe DK, Mordue D, Lingnau M, Sibley LD. Targeted disruption of the GRA2 locus in
Toxoplasma gondii decreases acute virulence in mice. Infect Immun. 1998;66:4176-82. PMID:9712765.

[55] Soldati D, Kim K, Kampmeier J, Dubremetz JF, Boothroyd JC. Complementation of a Toxoplasma
gondii ROP1 knock-out mutant using phleomycin selection. Mol Biochem Parasitol. 1995;74:87-97.PMID:8719248.

[56] Bohne W, Hunter CA, White MW, Ferguson DJ, Gross U, Roos DS. Targeted disruption of the bradyzoitespecific gene BAG1 does not prevent tissue cyst formation in Toxoplasma gondii. Mol Biochem Parasitol. 1998;92:291-01. PMID:9657333.

[57] Zhang YW, Kim K, Ma YF, Wittner M, Tanowitz HB, Weiss LM. Disruption of the Toxoplasma gondii bradyzoite-specific gene BAG1 decreases in vivo cyst formation. Mol Microbiol. 1999;31:691-01.
PMID:10027984.

[58] Capozzo AV, Cuberos L, Levine MM, Pasetti MF. Mucosally delivered Salmonella live vector vaccines
elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers. Infect Immun. 2004;72:4637-46. PMID:15271924.

[59] Lim SS, Othman RY. Recent advances in Toxoplasma gondii immunotherapeutics. Korean J Parasitol.
2014;52:581-93. PMID:25548409.

[60] Zhang J, He S, Jiang H, Yang T, Cong H, Zhou H, et al. Evaluation of the immune response induced by multiantigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine interleukin-12 plasmid in BALB/c mice. Parasitol Res. 2007;101:331-8. PMID:29296260.

[61] Qu D, Wang S, Cai W, Du A. Protective effect of a DNA vaccine delivered in attenuated Salmonella
typhimurium against Toxoplasma gondii infection in mice. Vaccine. 2008;26:4541-8. PMID:18590785.

[62] Del Rio L, Butcher BA, Bennouna S, Hieny S, Sher A, Denkers EY. Toxoplasma gondii triggers myeloid
differentiation factor 88-dependent IL-12 and chemokine ligand 2 (monocyte chemoattractant protein 1) responses using distinct parasite molecules and host receptors. J Immunol. 2004; 172(11):6954-60. PMID:15153515

[63] Zhang G, Huang X, Boldbaatar D, Battur B, Battsetseg B, Zhang H, et al. Construction of Neospora
caninum stably expressing TgSAG1 and evaluation of its protective effects against Toxoplasma gondii infection in mice. Vaccine. 2010;28:7243-7. PMID:20832493.

[64] Mevelec MN, Ducournau C, Bassuny Ismael A, Olivier M, Seche E, Lebrun M, et al. Mic1-3 Knockout
Toxoplasma gondii is a good candidate for a vaccine against T. gondii-induced abortion in sheep. Vet
Res. 2010;41:49. PMID:20385082.

[65] Mendes EA, Caetano BC, Penido ML, Bruna-Romero O, Gazzinelli RT. MyD88-dependent protective
immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is
mediated by CD8(+) T lymphocytes. Vaccine. 2011;29:4476-84. PMID:21549794.

[66] Zhang G, Huang X, Boldbaatar D, Battur B, Battsetseg B, Zhang H, et al. Construction of Neospora
caninum stably expressing TgSAG1 and evaluation of its protective effects against Toxoplasma gondii
infection in mice. Vaccine. 2010;28:7243-7. PMID:20832493.

[67] Bowie WR, King AS, Werker DH, Isaac-Renton JL, Bell A, Eng SB, et al. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet. 1997;350:173-7.
PMID:9250185.

[68] Dubey JP, Graham DH, da Silva DS, Lehmann T, Bahia-Oliveira LM. Toxoplasma gondii isolates of freeranging chickens from Rio de Janeiro, Brazil: mouse mortality, genotype, and oocyst shedding by cats.
J Parasitol. 2003;89:851-3. PMID:14533703.

[69] Zulpo DL, Headley SA, Biazzono L, da Cunha IA, Igarashi M, de Barros LD, et al. Oocyst shedding in
cats vaccinated by the nasal and rectal routes with crude rhoptry proteins of Toxoplasma gondii. Exp
Parasitol. 2012;131:223-30. PMID:22542988.

[70] Frenkel JK, Pfefferkorn ER, Smith DD, Fishback JL. Prospective vaccine prepared from a new mutant of
Toxoplasma gondii for use in cats. Am J Vet Res. 1991;52:759-63. PMID:1854103.

[71] Freyre A, Falcon J, Mendez J, Gastell T, Venzal JM. Toxoplasma gondii: cross-immunity against the
enteric cycle. Exp Parasitol. 2007;115:48-52. PMID:16828745.

[72] Silva Filho M, Erzinger E, Leme da Cunha I, Bugni F, Hamada F, Marangoni Marana E, et al. Toxoplasma
gondii: abortion outbreak in a goatherd from Southern Brazil. Semina-Ciencias Agrarias. 2008;29:887-
94.

[73] Roghmann MC, Faulkner CT, Lefkowitz A, Patton S, Zimmerman J, Morris JG, Jr. Decreased
seroprevalence for Toxoplasma gondii in Seventh Day Adventists in Maryland. Am J Trop Med Hyg.
1999;60:790-2. PMID:10344654.

[74] Jones JL, Parise ME, Fiore AE. Neglected parasitic infections in the United States: toxoplasmosis. Am J
Trop Med Hyg. 2014;90:794-9. PMID:24808246.

[75] Guo M, Dubey JP, Hill D, Buchanan RL, Gamble HR, Jones JL, et al. Prevalence and risk factors for
Toxoplasma gondii infection in meat animals and meat products destined for human consumption. J
Food Prot. 2015;78:457-76. PMID:25710166.

[76] Kringel H, Dubey JP, Beshah E, Hecker R, Urban JF, Jr. CpG-oligodeoxynucleotides enhance porcine
immunity to Toxoplasma gondii. Vet Parasitol. 2004;123:55-66. PMID:15265571.

[77] Burrells A, Benavides J, Canton G, Garcia JL, Bartley PM, Nath M, et al. Vaccination of pigs with the S48
strain of Toxoplasma gondii–safer meat for human consumption. Vet Res. 2015;46:47. PMID:25928856.